Want to see SPRY full AI Analyst Report?
SPRY Stock Chart & Stats
$5.72
-$0.17(-2.86%)
At close: 4:00 PM EDT
$5.72
-$0.17(-2.86%)
Day’s Range― - ―
52-Week Range$3.81 - $13.15
Previous CloseN/A
Volume674.69K
Average Volume (3M)1.50M
Market Cap
$420.66M
Enterprise Value$748.32M
Total Cash (Recent Filing)$143.84M
Total Debt (Recent Filing)$171.60M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 17, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding99,447,340
10 Day Avg. Volume1,608,488
30 Day Avg. Volume1,503,191
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap1.78
Enterprise Value/Revenue6.40
Enterprise Value/Gross Profit8.66
Enterprise Value/Ebitda-3.61
Forecast
1Y Price Target
$22.50Price Target Upside293.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.78
Revenue Forecast (FY)$128.58M
Bulls Say, Bears Say
Bulls Say
Commercial TractionRapid gains in revenue, market share, and prescriber adoption indicate that neffy is building commercial reach in its target market. Continued expansion among high-value prescribers can create a broader recurring sales base and improve operating leverage as the launch matures.
Needle-free Product PlatformNeffy’s needle-free delivery addresses the administration barrier associated with injectable epinephrine and gives ARS a distinct product format. That differentiation may support adoption among patients and providers while providing a platform for additional intranasal indications.
Pipeline ExpansionThe CSU program offers a potential expansion path beyond emergency anaphylaxis treatment while leveraging the company’s existing intranasal technology and commercial infrastructure. If development succeeds, a second indication could broaden the addressable market and improve platform value.
Bears Say
Persistent Operating LossesThe company’s current revenue base is not yet sufficient to cover its cost structure, producing substantial losses and cash consumption. Continued deficits can constrain investment capacity and make progress toward breakeven dependent on stronger sales growth and sustained expense control.
Fragile Capital StructureVery thin equity relative to debt leaves ARS with a limited financial cushion while losses continue. If cash burn persists, the company may need additional financing, and the stated capital structure increases exposure to refinancing or dilution pressure over the coming quarters.
Access And Net-revenue PressurePayer authorization requirements can slow prescribing and create administrative friction even where coverage exists, while gross-to-net deductions materially reduce realized revenue. These pressures could limit the conversion of market-share gains into cash generation and sustainable margins.
ARS Pharmaceuticals News
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $3.81 and its highest was $13.15 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $420.66M.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Nov 17, 2026 which is in 27 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.152.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.31.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 99,447,340 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went down -7.377%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (293.36% Upside)
$22.50 (293.36% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 98.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.91%
12-Months-Change
Fundamentals
Return on Equity
-256.67%
Trailing 12-Months
Asset Growth
-20.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
SPRY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging commercial momentum and a clear strategic reset with notable operational and financial challenges. Positive indicators include doubled overall market share (2.5% to 5%), an 8% share in field-targeted accounts, triple+ growth in unique prescribers, a completed sales-force expansion, hiring of an experienced CCO, and a plan to reduce cash-based SG&A by over 40% in H2 with a stated path to cash-flow breakeven by end of 2027. Offsetting these positives are high Q2 operating expenses (~$95.1M), elevated SG&A (~$77.6M), gross-to-net pressure near ~50%, manufacturing/short-dated inventory impacts on margins, payer prior-authorization friction (only ~57% without PA) and a modest delay in the CSU Phase IIb interim readout to Q1 2027. Overall, the company presented a constructive corrective plan but material execution and margin risks remain.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$22.50
▲(293.36% Upside)
Technical Analysis
DBV Technologies SA - American
―
Q32 Bio
―
SAB Biotherapeutics
―
Upstream Bio, Inc.
―
Evommune, Inc.
―
Ownership Overview
27.19% Insiders
6.92% Mutual Funds
0.43% Other Institutional Investors
56.12% Public Companies and
Individual Investors